http://www.lsis.com/goto/r103/rss 2010-06-23T11:11:02+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97f%FB%1C%7B%7Bx OBJECTIVE: To evaluate whether TAK-242, a small-molecule inhibitor of Toll-like receptor-4-mediated signaling, suppresses cytokine levels and improves 28-day all-cause mortality rates in patients with severe sepsis. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: A total of 93 intensive care units worldwide. PATIENTS: A total of 274 patients with severe sepsis and shock or respiratory failure. INTERVENTIONS: Patients were randomly assigned to receive a 30-min loading dose followed by 96-hr infusions of placebo, TAK-242 1.2 mg/kg/day, or TAK-242 2.4 mg/kg/day. MEASUREMENTS AND MAIN RESULTS: The primary pharmacodynamic end point was change in serum interleukin-6 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97f%FB%10%7E%7Dy PALO ALTO, Calif.-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies exclusive global agreement to develop and commercialize Hematide ¢/peginesatide, Affymax s investigational drug for the treatment of anemia in chronic renal failure patients. The payments were triggered by the achievement of database lock in the PEARL and EMERALD Phase 3 clinical trials, which evaluated Hematide to treat anemia in chronic renal failure patients. Affymax and Takeda are collaborating on the development of Hematide and will co-commercialize the product in the United (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FB%11u%7Cx PALO ALTO, Calif. & DEERFIELD, Ill. & OSAKA, Japan-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE, 4502), today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide ¢/peginesatide, for the treatment of anemia in chronic renal failure patients. The primary efficacy endpoint, the mean change in hemoglobin (Hb) from baseline, in each of the four Phase 3 studies (EMERALD 1, EMERALD 2, PEARL 1 and PEARL 2) met the statistical criteria for non-inferiority, when Hematide was compared to epoetin and darbepoetin, in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97f%FB%11%7Bvx PALO ALTO, Calif. & DEERFIELD, Ill. & OSAKA, Japan-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE, 4502), today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide ¢/peginesatide, for the treatment of anemia in chronic renal failure patients. The primary efficacy endpoint, the mean change in hemoglobin (Hb) from baseline, in each of the four Phase 3 studies (EMERALD 1, EMERALD 2, PEARL 1 and PEARL 2) met the statistical criteria for non-inferiority, when Hematide was compared to epoetin and darbepoetin, in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97f%FD%1Cu%7Cx ROME, June 17, 2010 (GLOBE NEWSWIRE) - XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines. All seven patients who enrolled in the trial displayed rapid reduction of intraocular inflammation and improvement in visual acuity or other ophthalmic measures following a single treatment with XOMA 052, a therapeutic antibody candidate that inhibits the inflammatory cytokine interleukin-1 beta (IL-1 beta). The preliminary results of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FD%1Cy%7E%7F WILMINGTON, N.C. & MORRISVILLE, N.C.-(BUSINESS WIRE)-PPD, Inc. (Nasdaq: PPDI) and Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today the successful completion of the spin-off of Furiex. As previously announced, PPD received a private letter ruling from the Internal Revenue Service that the dividend of common stock of Furiex to PPD shareholders qualifies as a tax-free distribution for U.S. income tax purposes. On June 14, 2010, shareholders of record of PPD as of June 1, 2010, received a pro rata dividend of one share of Furiex common stock for every 12 shares of PPD common stock they held. Fractional shares were paid in cash. PPD and Furiex now operate as two independent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FD%1Cx%7C%7C WILMINGTON, N.C., & MORRISVILLE, N.C.-(BUSINESS WIRE)-PPD, Inc. (Nasdaq: PPDI) and Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today the successful completion of the spin-off of Furiex. As previously announced, PPD received a private letter ruling from the Internal Revenue Service that the dividend of common stock of Furiex to PPD shareholders qualifies as a tax-free distribution for U.S. income tax purposes. On June 14, 2010, shareholders of record of PPD as of June 1, 2010, received a pro rata dividend of one share of Furiex common stock for every 12 shares of PPD common stock they held. Fractional shares were paid in cash. PPD and Furiex now operate as two independent (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97f%FE%12yys MORRISVILLE, N.C., Jun 11, 2010 (BUSINESS WIRE) - Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited has received pricing approval for NESINA(R) (alogliptin) in Japan. NESINA, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April 16, 2010. Furiex collaborated with Takeda to develop this product. Under the agreement with Takeda, upon receipt of both regulatory and pricing approvals, Furiex is entitled to receive a $7.5 million milestone payment from Takeda. "Receiving pricing approval for NESINA in Japan represents another important (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v103/%3B%97f%FE%12%7Evr The Healthcare Distribution Management Association (HDMA) recognized leading pharmaceutical and consumer product manufacturers with the presentation of 10 Distribution Industry Awards for Notable Achievements in Healthcare (DIANA). The winners were announced at the Association's inaugural Business & Leadership Conference in Orlando, Florida. "The 2010 DIANA winners demonstrate an abiding commitment to innovation and collaboration," said HDMA President and CEO John M. Gray. "These winning companies have shown creativity in introducing new products and services and establishing successful partnerships with their distributor peers in a way that benefits not just the healthcare supply chain (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v103/%3B%97f%FE%15z%7E%7F Millennium: The Takeda Oncology Company announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010. "Amyloidosis is a rare disease for which there are currently no approved therapies, creating a large unmet medical need in the patient community," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "Single-agent VELCADE activity yielded (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97f%FF%12yz%7E CHICAGO-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting. The data were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FF%12%7Dw%7F CHICAGO-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company s selective Aurora A kinase inhibitor. First clinical data were presented for MLN9708, Millenium s next proteasome inhibitor, and TAK-701, a hepatocyte growth factor (HGF) antibody. The first Phase II data for TAK-700, a selective 17,20 lyase inhibitor, were also presented. We are advancing our pipeline quickly. These preliminary results support (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FF%13tws CHICAGO-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy. We are very encouraged to see these unprecedented response rates in patients with previously untreated multiple myeloma, and these data support the synergy seen with VELCADE and other agents preclinically œWe are seeing (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FF%13ty%7B CHICAGO-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010. Single-agent VELCADE activity yielded impressive hematologic overall response rates in patients with relapsed or refractory disease. These data further support the rationale for Phase III studies of VELCADE in amyloidosis. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97f%FF%13tx%7E CHICAGO-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting. The data were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois. Through our broad ongoing clinical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97f%FF%10%7Cx%7B A new combination system, the oxidation of sulfides using aqueous NaOCl in the presence of a catalytic amount of imide under two-phase conditions, has been developed. The combination effectively converts various sulfides to the corresponding sulfoxides and sulfones. It was deduced that the imide could react with NaOCl to produce N-chloroimide, which would play roles of both the active oxidizing reagent and phase transfer catalyst. |-| J Org Chem. |-| Fukuda N, Ikemoto T. |-| Chemical Development Laboratories, CMC Center, Takeda Pharmaceutical Company Limited, Yodogawa-ku, Osaka 532-8686, Japan. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97f%FF%16%7F%7C%7F We examined the effects of exogenous melatonin and the time of its administration on core body temperature (CBT) and heart rate (HR) in cynomolgus monkeys. Doses of melatonin at 0.2, 2, 20 and 200 mg/kg were administered by oral gavage once daily at different times. With administration at 09.00 h, melatonin dose-dependently suppressed CBT and the effect reached statistical significance at 200 mg/kg. With administration at 16.00 h, the suppressive effect on CBT was not evident for several hours after administration possibly due to masking by the normal robust CBT decline. Unexpectedly, melatonin inhibited the normal CBT decline thereafter and this resulted in an upward shift of the CBT (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v103/%3B%97g%F6%10x%7Cr H. Lundbeck A/S (Lundbeck) announced that the first patients have been recruited and dosed in the new phase III programme using Lu AA21004 in major depression (MDD). The first patients have been recruited in Finland. As previously communicated filing of Lu AA21004 is anticipated in 2012. The extended phase III programme for Lu AA21004 is based on clinical data obtained until now. Available data show encouraging results for the potential efficacy and the tolerability profile of Lu AA21004: - A European based 560-patient placebo-controlled MDD study shows statistical significance on the primary efficacy endpoint across all tested doses. - Additionally a 639-patient relapse prevention study (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F6%10%7Ex%7D TOKYO-(BUSINESS WIRE)-9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 July 2, 2010. One of the hottest feature topics is "antibody drugs". One of the major reasons is the changing market, where new medicines are required because of "2010 problem", along with the aging society, where types of disorder are shifting into cancer from adult diseases. Under such circumstances, what kind of developments and challenges does antibody drug face? What kind of symptoms are on the table? Full information will be revealed in INT'L BIO FORUM & BIO EXPO JAPAN. Special Session 250 sessions cover the hottest topics in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97g%F6%15%7Cv%7B Metabolites of chemicals can often be ultimate genotoxic species, thus in vitro routine testing requires the use of rat liver S9. However, there is a question as to whether this represents an appropriate surrogate for human metabolism. We have previously demonstrated the usefulness of HepG2 transformants expressing major human cytochrome P450 (CYP) isoforms to assess the genotoxicity of metabolites. We further assessed the advantages of these transformants from the following 3 aspects. Firstly, the sensitivity of these transformants was confirmed with micronucleus (MN) induction by 7,12-dimethylbenz[a]anthracene or ifosfamide in transformants expressing the corresponding CYP1A1 or CYP2B6 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F7%1D%7Fwz CHICAGO-(BUSINESS WIRE)-The Illinois General Assembly late yesterday passed with overwhelming bipartisan support an Angel Tax Credit that incentivizes early-stage investment in Illinois technology companies. The Governor, whose office worked hard to pass the credit, is expected to sign the bill (SB 2093) or a second measure (SB 3710) with an identical Angel Tax Credit sent to the Senate yesterday by the House. Today s most powerful job engines are small innovative firms. Yesterday Illinois took a huge step in helping to create and attract those companies Knowledgeable observers expressed certainty the program would be enacted into law this spring or in November at the latest. The (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F7%10%7E%7B%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/52bee2/managed_care_pull) has announced the addition of the "Managed Care Pull - Through Excellence: From Formulary Access to Increased Market Share" report to their offering. Managed Care Pull - Through Excellence: From Formulary Access to Increased Market Share Winning a favorable managed care formulary position can be a Herculean task for pharmaceutical companies today, but successful brand leaders know that position alone doesnt guarantee increased market share. Savvy brand leaders develop and carry out extensive pull-through programs to drive product sales after a formulary win. The analyst (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F7%10%7Dx%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1e827b/new_product_planni) has announced the addition of the "New Product Planning: Role and Activities for Medical Marketing" report to their offering. New Product Planning: Role and Activities for Medical Marketing Leading pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs. The structure, activities, and resources of New Product Planning (NPP) groups are critical to focusing new product development and optimizing product portfolios. This benchmarking study examines the role and impact of NPP (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F8%12zz%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8e8b65/cardiovascular_dru) has announced the addition of the "Cardiovascular Drugs - Global Strategic Business Report" report to their offering. Cardiovascular Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million. Cardiovascular diseases can be prevented or treated using different classes of drugs. Broadly, the major classes of cardiovascular drugs include: ACE Inhibitors, Angiotensin II Receptor Blockers, Antiarrhythmics, Antithrombotics, Beta Blockers,. Calcium Channel Blockers, Antihyperlipidemics, and Others. The report (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F8%17%7Fz%7B BOTHELL, Wash. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is highly expressed on ALCL cells. Brentuximab vedotin has the potential to provide an improvement in patient care, which is our primary goal, and is another step toward global oncology leadership for Millennium. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97g%F8%17%7E%7Ey BOTHELL, Wash. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is highly expressed on ALCL cells. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F9%1D%7Dz%7D BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois. The presentation will highlight data from Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients who have been retreated upon relapse after discontinuing previous brentuximab vedotin therapy. Objective responses with brentuximab vedotin (SGN-35) retreatment in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F9%1D%7Cv%7B CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today announced that 71 oral and poster presentations featuring VELCADE (bortezomib) for Injection or the Company s oncology pipeline molecules will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 4-8, 2010. These data include five oral presentations on the use of VELCADE based therapy across a spectrum of multiple myeloma treatment settings. Our expertise in oncology development, as demonstrated by the success of VELCADE, has enabled us to quickly advance clinical development of our pipeline molecules in a variety of solid tumors. We re (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97g%F9%12x%7F%7B We investigated the effects of various emetic agents: cisplatin, apomorphine, lithium chloride (LiCl), rolipram, sibutramine, and the beta(3)-adrenoceptor (AR) agonist CL316243 on salivary amylase secretion in rats. We also determined the inhibitory effect of granisetron, a 5-HT(3)-receptor antagonist, on cisplatin-induced increased salivary amylase activity and the inhibitory effect of bilateral abdominal vagotomy on increases in salivary amylase activity induced by cisplatin and LiCl. Granisetron was administered 15 min before and 1 h after cisplatin administration. Cisplatin (10 - 15 mg/kg, i.v.) increased salivary amylase activity dose-dependently and induced an acute increase from 1.5 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F9%17zvz WALTHAM, Mass.-(BUSINESS WIRE)-BG Medicine, Inc., on behalf of the HRP Initiative, announced today that the HRP Initiative is soliciting research proposals and ideas from academic institutions, corporate entities and professional organizations to leverage biological specimens, imaging studies and data sets resulting from the BioImage study. BG Medicine launched the HRP Initiative in 2006 to advance the understanding, recognition and management of atherothrombosis, the underlying disease process that may lead to heart attack or stroke. The HRP Initiative is sponsored by Abbott Pharmaceuticals, AstraZeneca, Merck & Co., Philips Medical Systems and Takeda Pharmaceuticals. The BioImage (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97g%F9%17%7E%7Cy Liestal, Switzerland, May 20, 2010 - Santhera Pharmaceuticals announced today that its MICONOS Phase III study evaluating Catena/Sovrima for the treatment of Friedreich's Ataxia missed its primary endpoint. Trends towards improvement in the key neurological endpoint were however identified by a meta-analysis of all Santhera's Phase II and III studies in the same indication. MICONOS also confirmed that Catena/Sovrima is safe and well tolerated at doses of up to 2250 mg/day. The 12-month MICONOS (Mitochondrial Protection with Idebenone In Cardiac Or Neurological Outcome Study) study enrolled 232 primarily adult patients and evaluated the safety and efficacy of three doses of Catena/Sovrima (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F9%14tvx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0479b5/anemia_drugs_glo) has announced the addition of the "Anemia Drugs - Global Strategic Business Report" report to their offering. Anemia Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Anemia Drugs in US$ Million by the following segments: Short Acting ESAs (Erythropoiesis Stimulating Agents), and Long Acting ESAs (Erythropoiesis Stimulating Agents). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%F9%14tx%7E SCOTTSDALE, Ariz.-(BUSINESS WIRE)-The National Council for Prescription Drug Programs (NCPDP) announced today the second consecutive year of record-breaking attendance at its Annual Technology and Business Conference. The 2010 conference garnered the attention of stakeholders from across the healthcare industry pharmacy benefit managers, retail and independent pharmacies, software vendors, manufacturers, wholesale distributors, database management organizations, health plans, associations and others to discuss the future of healthcare information technology and healthcare reform, and celebrate the contributions the organization has made to transforming the industry. For over 30 years, (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v103/%3B%97g%FA%12zy%7F Highlighted Links http:/www.qumas.com http:/www.takeda.ie JERSEY CITY, NJ-(Marketwire - May 18, 2010) - QUMAS, the leading provider of Compliance Solutions to highly regulated companies, today announced that Takeda Ireland has selected QUMAS DocCompliance, an industry leading electronic document management system, for document control and compliance management across their manufacturing and quality operations. "Given the ever changing regulatory landscape, organizations find it extremely challenging to quickly identify, assemble, review, approve, and distribute all the relevant documents for compliance," said Ken Hayward, CTO QUMAS. "With QUMAS, Takeda Ireland can deploy a solution that (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%FA%12xvy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8fac3e/acute_coronary_syn) has announced the addition of the "Acute Coronary Syndrome - Global Strategic Business Report" report to their offering. Acute Coronary Syndrome - Global Strategic Business Report This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%FA%12x%7E%7D DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their diabetes research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the user The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. This dataset will also be relevant to those working in the area of drug delivery technologies, and to companies that supply labs involved in respiratory drug development. The database currently tags 202,240 individuals working in diabetes (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v103/%3B%97g%FB%13%7Dx%7C Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release (DDR) formulation. Takeda recently announced that the product trade name for dexlansoprazole in the United States would be changed to DEXILANT from KAPIDEX (dexlansoprazole). The medical community has been investigating whether patients who discontinue PPI therapy experience rebound gastric hypersecretion, and whether acid rebound is clinically relevant. Rebound acid hypersecretion is defined as an increase in gastric acid secretion above pretreatment (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97g%FB%16%7C%7Bx In a program to discover new small molecule diacylglycerol acyltransferase (DGAT)-1 inhibitors, screening of our in-house chemical library was carried out using recombinant human DGAT-1 enzyme. From this library, the lead compound 1a was identified as a new class of DGAT-1 inhibitor. A series of novel N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides 2 was designed from 1a, synthesized and evaluated for inhibitory activity against DGAT-1 enzyme. Among these compounds, N-(5-benzyl-4-phenyl-1,3-thiazol-2-yl)-4-(4,5-diethoxy-2-methylphenyl)-4-oxobutanamide 9 was found to exhibit potent inhibitory activity and good enzyme selectivities. Following administration in KKA(y) mice (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97g%FB%17u%7C%7D VANCOUVER, BRITISH COLUMBIA-(Marketwire - May 13, 2010) - Tekmira Pharmaceuticals Corporation (TSX: TKM), a leader in RNA interference (RNAi) therapeutics, today announced its financial and operational results for the first quarter ended March 31, 2010. Dr. Mark J. Murray, Tekmira's President and CEO, said, We are pleased with the progress we made in the first quarter of 2010 advancing of our clinical stage RNAi product candidates and supporting our partners as they advance programs using our technology. During the first quarter, we initiated a collaboration with Pfizer, expanded our collaboration with Takeda, completed a Phase 1 clinical trial for ApoB SNALP and made continued progress (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v103/%3B%97g%FB%17t%7Ez VANCOUVER, BRITISH COLUMBIA-(Marketwire - May 12, 2010) - Tekmira Pharmaceuticals Corporation (TSX:TKM), a leader in RNA interference (RNAi) therapeutics, announced today that it intends to apply to list its common shares on the NASDAQ stock market. Dr. Mark J. Murray, Tekmira's President and CEO, said, "We anticipate that listing our common shares on NASDAQ will broaden Tekmira's exposure to leading North American healthcare investors. Many of our peers have securities listed in the United States and we believe doing so is a logical step in the evolution of Tekmira to be appropriately valued as a leader in the RNAi field." "We are preparing to list our common shares on NASDAQ and believe (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97g%FB%15yy%7D GPR54 is a G protein-coupled receptor (GPCR) which was formerly an orphan receptor. Recent functional study of GPR54 revealed that the receptor has an essential role to modulate sex-hormones including GnRH. Though antagonists of GPR54 are expected to be novel drugs for sex-hormone dependent diseases such as prostate cancer or endometriosis, small molecule GPR54 antagonists have not been reported. We have synthesized a series of 2-acylamino-4,6-diphenylpyridines to identify potent GPR54 antagonists. Detailed structure-activity relationship studies led to compound 9l with an IC(50) value of 3.7nM in a GPR54 binding assay, and apparent antagonistic activity in a cellular functional assay. |-| (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97g%FC%1C%7C%7B%7F Press Release - OSAKA, Japan, May 12, 2010 - Takeda Pharmaceutical Company Limited (Takeda) today announced the start of its 2010-2012 Mid-Range Plan to transform the Company into a new Takeda. Under its 2006-2010 Mid-Range Plan, Takeda had made progress towards becoming a world-class pharmaceutical company. The Company achieved this by strengthening its oncology pipelines with the acquisition of Millennium Pharmaceuticals, unifying its U.S. sales network through the division of TAP 1) and its subsequent integration with TPNA 2), and enhancing its global governance structure with the establishment of position of leading International Operations and also the ones as Chief Scientific (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97g%FC%13%7C%7F%7F INTRODUCTION: Activated platelets facilitate blood coagulation by providing factor V and a procoagulant surface for prothrombinase. Here, we investigated the potential synergy of a potent factor Xa/prothrombinase inhibitor, TAK-442, plus aspirin or clopidogrel in preventing arterial thrombosis and whole blood coagulation. METHODS: Thrombus formation was initiated by FeCl(3)-induced rat carotid injury. Bleeding time was evaluated with the rat tail transection model. Whole blood coagulation was assessed by thromboelastographic examination (TEG) for which blood obtained from control, aspirin-, or clopidogrel-treated rats was transferred to a TEG analyzer containing, collagen or adenosine (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%FC%16z%7Fr BETHESDA, Md.-(BUSINESS WIRE)-Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today reported its consolidated financial results for the quarter ended March 31, 2010. We continue to focus on the further development of Amitiza for new indications and our other pipeline products such as Rescula ¢, cobiprostone and SPI-017 Sucampo reported a net loss of $0.3 million, or $0.01 per diluted share, for the first quarter of 2010, compared to a net loss of $1.8 million, or $0.04 per diluted share, for the same period in 2009, mainly due to lower research and development expenses. œWe continue to focus on the further development of Amitiza for new indications and our other pipeline products such as (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v103/%3B%97g%FC%16xvr CAMBRIDGE, Mass. & OSAKA, Japan-(BUSINESS WIRE)-Takeda Pharmaceutical Company Limited ( œTakeda,  TSE:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company ( œMillennium ) today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. ( œJanssen Pharma ) for VELCADE (bortezomib) for Injection, a treatment for patients with multiple myeloma. Janssen Pharma launched VELCADE in Japan in 2006, where it is approved for relapsed multiple myeloma. VELCADE is currently approved in more than 90 countries and has treated more than 160,000 patients worldwide. In 2009, global sales were in excess of $1 billion. The co-promotion (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%FD%13yws PALO ALTO, Calif.-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2010. The net loss for the first quarter of 2010 was $7.9 million compared to a net loss of $21.7 million for the first quarter of 2009. Affymax recognized revenue for the quarter ended March 31, 2010 of $34.7 million compared to $25.9 million for the quarter ended March 31, 2009. The increase in revenue was the result of increased collaboration revenue from its partnership with Takeda Pharmaceutical Company Limited, under their 2006 collaboration for development of Affymax s compound, Hematide ¢. Research and development expenses for the quarter ended (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v103/%3B%97g%FD%11%7C%7Er NEW ORLEANS, LA-(Marketwire - May 5, 2010) - What: Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release" (DDR) formulation. Takeda recently announced that the product trade name for dexlansoprazole in the United States would be changed to DEXILANT from KAPIDEX" (dexlansoprazole). The medical community has been investigating whether patients who discontinue PPI therapy experience rebound gastric hypersecretion, and whether acid rebound is clinically relevant. Rebound acid hypersecretion is defined as an (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v103/%3B%97g%FD%16zwz CAMBRIDGE, Mass.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights. The first quarter and recent period has been very productive as we continued to execute on our mission of building a top-tier biopharmaceutical company founded on RNAi œThe first quarter and recent period has been very productive as we continued to execute on our mission of building a top-tier biopharmaceutical company founded on RNAi,  said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. œJust recently we presented new pre-clinical data from (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v103/%3B%97g%FE%14%7C%7C%7F Reuters: "The controversy surrounding a GlaxoSmithKline Plc diabetes drug points to a need for changes in the way the U.S. Food and Drug Administration handles safety issues, agency critics told lawmakers on Wednesday. The FDA is taking a new look at the safety of Glaxo's Avandia pill, which carries a warning about heart risks. The manufacturer says the drug is safe and effective, and the FDA is advising patients to keep taking the drug as directed. Two drug safety reviewers have recommended that the drug come off the market after concluding it was more dangerous to the heart than rival drug Actos by Takeda Pharmaceutical Co Ltd. That has prompted new calls for more independence and power (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v103/%3B%97g%FF%10%7D%7Fs The rising prevalence of gout has led the pharmaceutical industry to rediscover what it had considered a forgotten disease. In April 2009, the Food and Drug Administration (FDA) approved febuxostat (Takeda Pharmaceuticals; Deerfield, IL), the first new urate-lowering gout drug in more than 40 years. In August 2009, the FDA approved colchicine for the treatment of acute gout. Several other pharmaceutical companies are also conducting clinical trials to test new drugs for acute and chronic gout. This article reviews new drugs and drugs in development in the management of acute and chronic gout. |-| Curr Rheumatol Rep. |-| Schlesinger N. |-| Division of Rheumatology, Department of Medicine, (…)